Core Viewpoint - SelectQuote Inc. is facing significant investor pressure due to a sharp decline in share prices following disappointing quarterly earnings and ongoing legal issues related to alleged violations of the False Claims Act [1][3]. Financial Performance - For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share [2]. - The company posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12% [2]. Legal Issues - The U.S. Department of Justice (DOJ) announced a lawsuit on May 1, 2025, alleging that SelectQuote and other health insurers violated the False Claims Act in their marketing of Medicare Advantage plans [3][4]. - The lawsuit claims that from 2016 to at least 2021, SelectQuote received significant payments from insurers for Medicare Advantage enrollments, but allegedly steered beneficiaries toward higher-commission plans, disregarding their suitability [4]. Investor Sentiment - The combination of poor earnings and serious legal allegations has heightened concerns regarding SelectQuote's financial stability and operational integrity [5]. - Hagens Berman, a law firm investigating SelectQuote, emphasizes that the recent earnings figures raise existing concerns about the company's alleged steering tactics in light of the DOJ's allegations [5].

URGN Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, May 29, 2025 /PRNewswire/ -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently ...

Core Viewpoint - Maravai LifeSciences experienced a significant share price drop of 21% following the announcement of a delay in its Q4 and FY 2024 earnings release, raising concerns about its financial reporting and internal controls [1][3]. Financial Reporting Issues - The company is assessing a goodwill impairment charge related to a previous acquisition [3]. - Maravai acknowledged an overstatement of Q2 2024 revenue by approximately $3.9 million due to improper revenue recognition practices [3]. - The company is evaluating the adequacy of its internal controls over financial reporting, particularly concerning revenue recognition [3]. Market Reaction - Following the announcement, an analyst from Baird downgraded Maravai's rating from outperform to neutral and reduced the price target from $9 to $3 [4]. - The news prompted an investigation by Hagens Berman into potential accounting misconduct, urging affected investors to report their losses [2][4].

SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial and its design to contact the firm's attorneys.Class Period: Nov. 2, 2022 – Dec. 19, 2024Lead Plaintif ...